Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05107193 No longer available - Solid Tumors Clinical Trials

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Start date: n/a
Phase:
Study type: Expanded Access

Gene fusions are defined as two separate genes joined together (gene 1, gene 2), generating a novel fusion gene. NRG1 fusions are rare and complex with regard to the fusion/fusion partner. The specific NRG1 gene fusion will be identified by a specialized molecular testing lab.

NCT ID: NCT04854369 No longer available - Prostatic Neoplasms Clinical Trials

68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)

Firefly
Start date: n/a
Phase:
Study type: Expanded Access

This is a prospective, Phase 2, single-center, open-label study of 68Ga-PSMA-11 PET scans in patients with biochemically recurrent prostate cancer or those diagnosed and untreated with high risk or very high risk localized prostate cancer, or oligometastatic (defined as three or fewer metastatic lesions on conventional imaging) prostate cancer (using NCCN classification for localized disease). Approximately 300 patients are planned for enrollment in this study, divided into two cohorts. Cohort A will be 225 patients in the recurrent setting. Cohort B will be 75 patients in the up-front newly diagnosed setting. After a screening period (6-week window), eligible patients will undergo baseline assessments as per the Schedule of Study Activities. Patients will receive a single dose of 68Ga-PSMA-11 and undergo a PET/CT or PET/MRI imaging study.

NCT ID: NCT03914872 No longer available - Solid Tumor, Adult Clinical Trials

Expanded Access Neoantigen Vaccine in Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access use study. Safety data will be collected from participants.

NCT ID: NCT03874455 No longer available - Clinical trials for Renal Cell Carcinoma

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory alternative treatments must have been tried without clinical success. Patients with conditions not listed under "conditions" below are not eligible for the tazemetostat EAP.

NCT ID: NCT02889445 No longer available - Advanced Cancer Clinical Trials

A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers

Start date: n/a
Phase:
Study type: Expanded Access

4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain via Pgp (p-glycoprotein) (1). DM-CHOC-PEN has completed Phase I/II trials in humans with primary and secondary tumors involving the brain with success. Complete remissions in both primary (astrocytomas, GBM) and metastatic lung cancers. This trial is open for adolescent and young adults (AYA) subjects with advanced cancer - brain involvement is not required.

NCT ID: NCT02824094 No longer available - Neoplasms Clinical Trials

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Start date: n/a
Phase: N/A
Study type: Expanded Access

Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.

NCT ID: NCT02473653 No longer available - Metastatic Cancer Clinical Trials

Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer

Start date: n/a
Phase: N/A
Study type: Expanded Access

Immune-based therapies (vaccines) are a new focus of clinical investigation. These therapies try to assist a patient's immune system (a system in our bodies that protects us against infection) in killing tumors. One form of such therapy is the dendritic cell combined with HER-2/neu (a type of protein over-expressed in some cancers) vaccine. Dendritic cells are immune cells that can tell your immune system to fight infection. In laboratory testing, these cells may also help the immune system attack tumors such as breast, kidney cancer or skin cancer. The purpose of this research study is to determine if it is both possible and safe to administer" this vaccine to patients with any HER2+ cancer.

NCT ID: NCT01980732 No longer available - Carcinoid Tumors Clinical Trials

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

NCT ID: NCT01945164 No longer available - Advanced Malignancy Clinical Trials

XL999 Administered Intravenously to a Subject With Advanced Malignancies

Start date: April 2010
Phase: N/A
Study type: Expanded Access

Cancer is a worldwide clinical and economic problem. Conventional approaches to treating cancer include surgery, radiotherapy, and cytotoxic chemotherapy as single modalities or as combined therapies. Recently, targeted therapies including antibodies and small molecule inhibitors have also demonstrated clinical benefit. It is now possible to study different genetic lesions involved in cancer types due to advances in genomic methodologies. The investigational drug in this study, XL999 inhibits multiple receptor tyrosine kinases, including VEGF receptor (VEGFR2/KDR), platelet derived growth factor receptors (PDGFRβ), fms-like tyrosine kinase receptor 3 (FLT3), fibroblast growth factor receptors (FGFR1, FGFR3), RET, and KIT, and thus, interferes with multiple cellular processes simultaneously and will likely have effects on the integrity of tumor neovasculature and angiogenesis. Together with the ability to induce a novel cell cycle arrest, the spectrum of activities that XL999 exhibits may reduce both tumor cell proliferation and angiogenesis in the clinic. The rationale and purpose of this maintenance study is to allow a subject receiving clinical benefit from XL999 to continue treatment.